SCHEDULE 13G/A: Soleus Capital Entities Disclose 6.4% Stake in Rigel Pharmaceuticals
Beneficial Ownership Report
Soleus Capital Master Fund, L.P. and its affiliated entities, including Guy Levy, have disclosed a beneficial ownership of 6.4% in Rigel Pharmaceuticals, Inc., holding 1,130,679 shares as of December 31, 2024.
Summary
- Soleus Capital Master Fund, L.P., along with Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy, collectively reported beneficial ownership of 1,130,679 shares of Rigel Pharmaceuticals, Inc. common stock.
- This ownership represents 6.4% of Rigel Pharmaceuticals' outstanding common stock.
- The percentage is calculated based on 17,615,040 shares of common stock outstanding as of November 4, 2024, as reported in Rigel's Quarterly Report on Form 10-Q for the period ended September 30, 2024.
- The reporting persons disclaim beneficial ownership of these shares except for the purpose of determining their obligations under Section 13(d) of the Exchange Act.
- The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, nor as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: The document is a factual, regulatory filing disclosing beneficial ownership and does not contain subjective language or performance data that would indicate a positive or negative sentiment.
Future Outlook
NA
Industry Context
This Schedule 13G filing is a standard disclosure of significant passive ownership by an institutional investor in a publicly traded pharmaceutical company. It does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 2024-09-30 | End of period for Rigel Pharmaceuticals' Quarterly Report on Form 10-Q. |
| 2024-11-04 | Date as of which 17,615,040 shares of Rigel Pharmaceuticals common stock were outstanding, as reported in the Form 10-Q. |
| 2024-11-07 | Date Rigel Pharmaceuticals filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024. |
| 2024-12-31 | Date of event which requires filing of this statement (beneficial ownership calculation date). |
| 2025-02-11 | Filing date of the Schedule 13G Amendment No. 3. |
Keywords
Rigel Pharmaceuticals, Soleus Capital, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Pharmaceuticals, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.